武清区龙济泌尿是否全周上班武清区龙济泌尿外科男科专科,天津武清区龙济泌尿专科坐什么车去,武清市龙济专科医院,天津省龙济医院医院男科,天津市龙济医院医包皮,天津市武清区龙济男科医院什么地方,天津市武清区龙济医院治疗男科可以吗

BEIJING, July 3 (Xinhuanet) -- The Atlantis mission to be launched by NASA on July 8 will not be an end to the space age, as some media suggest.Although it is the final mission of the space shuttle, it will open up "the next chapter" in the United States' space exploration, NASA's administrator Charles Bolden Jr said at the National Press Club in Washington on Friday."When I hear people say - or listen to media reports - that the final shuttle flight marks the end of US human space flight, I have to say . . . these folks must be living on another planet," he said."As a former astronaut and the current NASA administrator, I'm here to tell you that American leadership in space will continue for at least the next half-century because we have laid the foundation for success - and for NASA, failure is not an option," he said.NASA administrator Charles Bolden Jr drew a lot of media attention during his speech at the National Press Club in Washington DC.One of the foundations is the "unprecedented" research capabilities the International Space Station (ISS) now possesses, largely thanks to the space shuttle missions.Although some media imply that "the game will be up" once the ISS is out of orbit in 2020, he said the splendid research results and rich knowledge astronauts and scientists have accumulated through more than 1,200 experiments since 1998 have laid out "a stepping-stone to the rest of the solar system and the tip of what comes next".As NASA turns a new page, it will "focus on deep space exploration", while leaving US private companies to operate low Earth orbit transportation systems for tourism and business, he said.NASA will develop "a deep space crew vehicle and an evolvable heavy-lift rocket," he said. The moon, asteroids and Mars will be the next destinations for humans to live and work, he said."We will maintain and grow US leadership in space and derive all the benefits that flow from it. Tomorrow's space program is taking shape right now," he said.

CHICAGO, Aug. 25 (Xinhua) -- Gold futures on the COMEX Division of the New York Mercantile Exchange on Thursday bounced off the biggest drop since March 2008, as the weakness in stock market enhanced appeal of gold as a safe-have investment.The most active gold contract for Dec. delivery gained 5.9 U.S. dollars, or 0.3 percent, to 1,763.2 dollars per ounce. The metal suffered on Wednesday the biggest one-day drop since March 19, 2008.Market analysts said that gold extended losses in earlier trading, hit by a margin-requirement increase, but the drop in global stock market gave a push to the metal. Both Dow Jones industrial average and S&P 500 declined on Thursday after a 3-day rise as a government report showed U.S. jobless claims rose last week.Besides, market hearsay went that Germany might be next to get a sovereign-debt downgrade, adding to the positive tone on gold market. German equity market also suffered sharp drop in the day.Many market watchers remained long-term bullish attitude toward gold although they said the precious metal could correct further in the short term. A trader noted that the fundamental factors driving uncertainty and fears are all still there.Expectations are growing that the Federal Reserve Chairman Ben Bernanke would not provide any form of stimulus in a speech scheduled for Friday at a yearly gathering of central bankers in Jackson Hole.Silver for Sept. delivery also rose 1.583 dollars, or four percent, to 40.745 dollars per ounce. Platinum for Oct. delivery lost 3.9 dollars, or 0.2 percent, to 1822.4 dollars per ounce.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, Sept. 2 (Xinhuanet) -- Firefighters who worked in the wreckage of the World Trade Center in 2001 were 19 percent more likely to develop cancer than those who were not there, according to a study.The study, published Thursday in the British medical journal The Lancet, surveyed cancer occurrence in nearly 10,000 male firefighters in the seven years after Sept. 11, 2001. (There were too few women to create a meaningful sample size.)The 9/11 attacks occurred on Tuesday, Sept. 11, 2001. As a result, the World Trade Center collapsed, and nearly 3,000 Americans killed. Among the 2,753 victims killed in the World Trade Center were 343 firefighters.There were 263 cancer cases in the exposed population, showing a cancer rate 19 percent higher than that of the group not exposed.The study indicated that cancers like melanoma, non-Hodgkin’s lymphoma, thyroid and prostate cancer occurred more frequently among exposed firefighters than in the general population. But occurrences of lung cancer did not increase.The findings “provide information that there may be a significant cancer risk for these people”, said Dr. James Melius, the administrator of the New York State Laborers’ Health and Safety Trust Fund and one of the peer reviewers of the study.But the results were far from conclusive. “This is not an epidemic,” said Dr. David J. Prezant, a lead researcher and the chief medical officer for the New York Fire Department.